Cycle Pharmaceuticals Partners with LeMed for Exclusive Distribution of HARLIKU™ Treatment in the U.S. Cycle Pharmaceuticals has chosen LeMed Specialty Pharmacy for exclusive U.S. distribution of HARLIKU™, the sole FDA-approved treatment for Alkaptonuria. This partnership aims to enhance patient care.

Cycle Pharmaceuticals Partners with LeMed for Exclusive Distribution of HARLIKU™ Treatment in the U.S. #United_States #Bronx #HARLIKU™ #Alkaptonuria #Cycle_Pharmaceuticals